Trazodone After Bariatric Surgery: What Clinicians and Patients Need to Know

What surgery changes, and what has not been measured

Roux-en-Y gastric bypass leaves a small gastric pouch and routes food past the proximal small bowel. Sleeve gastrectomy removes most of the stomach without bypassing bowel.

How much surgery matters for absorption depends on the drug. A systematic review of 26 studies (15 case reports or case series covering 12 drugs and 11 non-randomized controlled studies covering 15 drugs) concluded that the effect of bariatric surgery on drug absorption is drug-specific. Evidence of reduced absorption was most consistent for cyclosporine, thyroxine, phenytoin and rifampin, and the authors wrote that individual dose adjustment and therapeutic monitoring may be required and that controlled studies of modern procedures are needed [2].

An in vitro model that recreated the stomach environment before and after Roux-en-Y gastric bypass found that 10 of 22 psychiatric medication preparations dissolved significantly less, and 2 significantly more, in the post-surgery conditions. The authors called for in vivo studies of serum drug levels after surgery [3]. That model used laboratory conditions, not patients.

The size and direction of any change in trazodone exposure after surgery are therefore not established.

What the label says, regardless of surgery

The current label describes trazodone as a selective serotonin reuptake inhibitor and 5-HT2 receptor antagonist, a triazolopyridine derivative rather than a tricyclic, and lists one indication: major depressive disorder in adults. It is not approved for children. The label has no insomnia indication and no insomnia dose [1].

The labeled dosing starts at 150 mg per day in divided doses and rises by 50 mg per day every 3 to 4 days, usually to no more than 400 mg per day in divided doses for outpatients; severely depressed inpatients may go to 600 mg per day [1]. The label says to consider a lower dose when trazodone is taken with a strong CYP3A4 inhibitor, and to consider a higher dose with a strong CYP3A4 inducer [1].

On administration, the label says to take the tablets shortly after a meal or light snack and to swallow them whole or break them along the score line; it says not to chew or crush them [1]. In 8 healthy volunteers given 100 mg, the mean time to peak was 1.3 hours without food and 2.0 hours with food; food lowered peak concentration from 1.88 to 1.47 micrograms/mL without changing total absorption, and bioavailability was 63 to 65% [4].

What to watch for, from the label

Blood pressure on standing. The label links trazodone's alpha-1 adrenergic blockade to postural hypotension, and orthostatic hypotension and syncope are listed as reported effects. In the outpatient MDD trials, hypotension occurred in 4% of trazodone patients versus 0% on placebo, and syncope in 5% versus 1%. Drowsiness was 41% versus 20%, dizziness or lightheadedness 28% versus 15%, and blurred vision 15% versus 4% (trazodone n=157, placebo n=158) [1].

Heart rhythm. The label states that trazodone prolongs the QT/QTc interval, and that torsades de pointes and ventricular tachycardia have been reported after marketing at doses of 100 mg per day or less with the immediate-release form. It says to avoid the drug in people with known QT prolongation, a history of cardiac arrhythmia, low potassium or magnesium, congenital long QT, or during the initial recovery phase after a heart attack, and to avoid combining it with other QT-prolonging drugs such as quinidine, procainamide, amiodarone, sotalol, ziprasidone, chlorpromazine, thioridazine or gatifloxacin, or with CYP3A4 inhibitors such as itraconazole, clarithromycin or voriconazole [1].

Serotonin syndrome. It can occur with trazodone alone, and the risk rises with other serotonergic drugs (triptans, tricyclics, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's wort) and with MAOIs, which are the label's only contraindication. Listed signs include agitation, hallucinations, fast heart rate, labile blood pressure, sweating, fever, tremor, rigidity, myoclonus, seizures, nausea, vomiting and diarrhea [1].

Mood and suicidality. The boxed warning reports that antidepressants increased suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. The pooled table shows 14 additional cases per 1,000 treated under age 18, 5 additional at ages 18 to 24, 1 fewer at ages 25 to 64 and 6 fewer at 65 and older. The label says to monitor for clinical worsening and new suicidality [1].

Sedation and alcohol. The label says trazodone may enhance the effects of alcohol, barbiturates and other CNS depressants, and that overdose deaths have occurred when it was taken with alcohol or other sedatives [1].

Interactions that matter most

Trazodone is metabolized by CYP3A4. In a blinded four-way crossover study of 10 healthy volunteers, 50 mg of trazodone taken with low-dose ritonavir (four 200 mg doses) cut apparent oral clearance from 155 to 75 mL/min, lengthened half-life from 6.7 to 14.9 hours and raised peak concentration from 842 to 1,125 ng/mL, with more sedation and fatigue; three volunteers had nausea, dizziness or hypotension and one fainted [5]. In human liver microsomes and expressed enzymes, only CYP3A4 produced the active metabolite m-chlorophenylpiperazine, and ketoconazole blocked that step [6]; ritonavir and indinavir were potent inhibitors in the same system [7]. A 2025 in vitro study found CYP2D6, CYP2C19 and flavin monooxygenases contribute to other, inactive metabolites, with CYP3A4 still the primary enzyme [8].

The direction matters. Trazodone is a substrate, not an inhibitor: the label does not list it as a CYP inhibitor or inducer, and it does not appear in the FDA's substrate, inhibitor or inducer index tables [1][9]. The label does say trazodone can raise digoxin or phenytoin levels, with a recommendation to measure levels before starting and reduce those drugs' doses if needed. It also says prothrombin time with warfarin may rise or fall, so INR should be monitored when trazodone is started or stopped [1]. Aspirin, NSAIDs, other antiplatelets and anticoagulants may add to bleeding risk [1].

If trazodone is being used for depression

A meta-analysis of 68 publications found depression in 19% (95% CI 14% to 25%) of people seeking or undergoing bariatric surgery. Surgery was consistently associated with postoperative decreases in depression prevalence (7 studies, 8% to 74% decrease) and symptom severity (6 studies, 40% to 70% decrease) [10]. These figures describe surgery patients in general, not trazodone; the label's adult MDD regimen above is the dosing it gives [1].

The insomnia question

Trazodone is widely used off-label for sleep, but the published support is weak. A 2005 review located 18 studies of trazodone for insomnia and concluded that the evidence is very limited. Most studies were small, often conducted in depressed patients and often lacked objective measures. The review judged it uncertain whether the risk-benefit ratio warrants trazodone in non-depressed people with insomnia [11]. It was not conducted in post-bariatric patients.